Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.52 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.52 |
| ▸ | DGKA | P23743 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | PAM | P19021 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6374914 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1DGKATLR2 | |
| SCHEMBL3284700 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1DGKATLR2 | |
| SCHEMBL642918 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1DGKATLR2 | |
| SCHEMBL27820405 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1DGKATLR2 | |
| SCHEMBL8195094 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1DGKATLR2 | |
| SCHEMBL597985 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1DGKATLR2 | |
| SCHEMBL2909093 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1DGKATLR2 | |
| SCHEMBL8581727 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1DGKATLR2 | |
| SCHEMBL128842 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1DGKATLR2 | |
| SCHEMBL27820502 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1DGKATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114026062-B | NεProcess for the preparation of crystals of long-chain acyl lysines and compositions comprising the crystals | 味之素株式会社 | 2025-05-09 | — | — | CN | claimed |
| EP-4501307-A1 | POWDER COMPOSITION | AJINOMOTO CO., INC. (JP) | 2025-02-05 | — | — | EP | claimed |
| US-20250009626-A1 | POWDER COMPOSITION | AJINOMOTO CO., INC. (JP) | 2025-01-09 | — | — | US | claimed |
| WO-2023191097-A1 | POWDER COMPOSITION | 味の素株式会社 | 2023-10-05 | — | — | WO | claimed |
| US-10195127-B2 | Cosmetic composition | AJINOMOTO CO., INC. (JP) | 2019-02-05 | — | — | US | claimed |
| US-20160000676-A1 | COSMETIC COMPOSITION | AJINOMOTO CO., INC. (JP) | 2016-01-07 | — | — | US | claimed |
| WO-2009091582-A1 | PRODUCTION OF R-α-LIPOIC ACID BY FERMENTATION USING GENETICALLY ENGINEERED MICROORGANISMS | INDIGENE PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | claimed |
| CN-114026062-B | NεProcess for the preparation of crystals of long-chain acyl lysines and compositions comprising the crystals | 味之素株式会社 | 2025-05-09 | — | — | CN | disclosed |
| EP-4005552-B1 | HYDROPHILIZED ORGANIC POWDER AND COSMETIC INCLUDING HYDROPHILIZED ORGANIC POWDER | MIYOSHI KASEI INC (JP) | 2025-05-07 | — | — | EP | disclosed |
| EP-4501307-A1 | POWDER COMPOSITION | AJINOMOTO CO., INC. (JP) | 2025-02-05 | — | — | EP | disclosed |
| US-20250009626-A1 | POWDER COMPOSITION | AJINOMOTO CO., INC. (JP) | 2025-01-09 | — | — | US | disclosed |
| US-12168068-B2 | Hydrophilized organic powder and cosmetic including hydrophilized organic powder | MIYOSHI KASEI, INC. (JP) | 2024-12-17 | — | — | US | disclosed |
| CN-114126578-B | Hydrophilized organic powder and blend with cosmetic containing hydrophilized organic powder | 三好化成株式会社 | 2024-11-26 | — | — | CN | disclosed |
| EP-0908491-B1 | Thermoplastic resin composition, agent for improving thermal aging resistance of thermoplastic resin, and resin molded article obtained therefrom | AJINOMOTO KK (JP) | 2003-02-26 | — | — | EP | disclosed |
| EP-1086985-A2 | Thermoplastic resin composition, agent for improving thermal aging resistance of thermoplastic resin, and resin molded article obtained therefrom | Ajinomoto Co., Inc. (JP) | 2001-03-28 | — | — | EP | disclosed |
| US-6147148-A | WHERE THE ESTER HAS A DEGREE OF ESTERIFICATION OF NOT MORE THAN 50% | AJINOMOTO CO., INC. (JP) | 2000-11-14 | — | — | US | disclosed |
| EP-0908491-A2 | Thermoplastic resin composition, agent for improving thermal aging resistance of thermoplastic resin, and resin molded article obtained therefrom | Ajinomoto Co., Inc. (JP) | 1999-04-14 | — | — | EP | disclosed |
| EP-0384416-B1 | A pharmaceutical composition containing hydantoin derivative | SANWA KAGAKU KENKYUSHO CO (JP) | 1993-11-03 | — | — | EP | disclosed |
| WO-1990009791-A1 | PHARMACEUTICAL COMPOSITION CONTAINING HYDANTOIN DERIVATIVE | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1990-09-07 | — | — | WO | disclosed |
| EP-0384416-A1 | A pharmaceutical composition containing hydantoin derivative | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000676-A1 | COSMETIC COMPOSITION | CUTA, H1-0, AADAT | GNAI3 3261/4885GNAO1 3493/4885GNAI1 2420/4885 |
| US-10195127-B2 | Cosmetic composition | CUTA, H1-0, AADAT | GNAI3 3261/4885GNAO1 3493/4885GNAI1 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.